Novavax (NVAX) Scheduled to Post Earnings on Friday

Novavax (NASDAQ:NVAX) is scheduled to be issuing its quarterly earnings data before the market opens on Friday, May 10th. Analysts expect the company to announce earnings of ($1.04) per share for the quarter. Novavax has set its Q1 2024 guidance at EPS and its FY 2024 guidance at EPS.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.95). The firm had revenue of $291.34 million for the quarter, compared to the consensus estimate of $310.96 million. The company’s revenue for the quarter was down 18.5% on a year-over-year basis. During the same period last year, the firm posted ($2.28) EPS. On average, analysts expect Novavax to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Novavax Price Performance

NVAX opened at $4.55 on Wednesday. Novavax has a 1-year low of $3.53 and a 1-year high of $11.36. The stock has a market cap of $638.83 million, a P/E ratio of -0.83 and a beta of 1.63. The stock’s 50 day simple moving average is $4.67 and its 200 day simple moving average is $4.99.

Analyst Ratings Changes

Separately, HC Wainwright lowered their target price on Novavax from $35.00 to $19.00 and set a “buy” rating on the stock in a report on Friday, March 1st.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.